Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660382 · ClinicalTrials.gov registry record · Phase 3
Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis
A Phase 3 study of Otomycosis, sponsored by Hill Dermaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 7
- Study locations
NCT05660382: Recruiting Phase 3 study of Otomycosis, sponsored by Hill Dermaceuticals.
NCT05660382 is a Phase 3 study of Otomycosis that is actively recruiting participants, run by Hill Dermaceuticals. The registered enrollment target is 100 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05660382, a Phase 3 study of Otomycosis, is actively recruiting participants, sponsored by Hill Dermaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use the drug or placebo. After 14 days of using the drug or placebo, the participants will be examined by the researcher and graded on how well the drug worked on the ear(s) fungal infection. Participants will also be checked and asked for any bad side effects from the drug or the placebo.
Primary Outcome
A score of 0 for fungal elements, pruritus, debris, and aural fullness
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Miconazole (2%) oil and mineral oil
Study Locations (7)
South Carolina
- Charleston ENT Associates, LLC - North Charleston
- Carolina ENT - Orangeburg
- Spartanburg / Greer ENT & Allergy - Spartanburg
California
- Head and Neck Surgery Specialist - Chula Vista
Kentucky
- Advanced ENT & Allergy - Louisville
Texas
- Alamo ENT Associates - San Antonio
Utah
- ENT Center Of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-03-02 |
| Est. Completion | 2024-11 |
| Phase | Phase 3 |
What NCT05660382 shows while recruiting
NCT05660382 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Otomycosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05660382 lists 7 locations in 5 states (South Carolina, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05660382 about?
NCT05660382 is a clinical study titled "Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis". The goal of this clinical trial is to prove the that miconazole oil works well on fungal infections of the ears, by comparing the drug with a placebo. The researcher or the participants will not know if they are getting the drug or the placebo. The researcher will show the participants how to use th...
What is the current status of trial NCT05660382?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-03-02. Estimated completion is 2024-11.
What conditions does trial NCT05660382 study?
This clinical trial studies the following conditions: Otomycosis.
What interventions are being tested in trial NCT05660382?
The interventions under investigation include: Placebo (OTHER), Miconazole (2%) oil and mineral oil (DRUG).
Who is sponsoring clinical trial NCT05660382?
This trial is sponsored by Hill Dermaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660382 being conducted?
This trial has 7 study locations across California, Kentucky, South Carolina, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05660382's enrollment target sits among peer trials
100 1682nd of 2000 higher than 288 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI